Research programme: mitochondrial disorders therapeutics - Mitobridge

Drug Profile

Research programme: mitochondrial disorders therapeutics - Mitobridge

Alternative Names: MA-0217; MTB-2; PPARδ modulators - Mitobridge

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitobridge
  • Class Small molecules
  • Mechanism of Action Peroxisome-proliferator-activated-receptor-delta-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Kidney disorders; Mitochondrial disorders

Most Recent Events

  • 06 Nov 2017 Mitobridge plans a clinical trial for Acute kidney injury in USA
  • 11 Aug 2017 Preclinical trials in Kidney disorders in USA (PO) (Mitobridge pipeline, August 2017)
  • 07 Dec 2016 Astellas plans to file an IND application with the US FDA for Mitochondrial disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top